Herpes simplex virus infections Exhibits Emerging Pipeline with 20 Drug Candidates

The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates, of which one drug candidate is in Phase III stage, five drug candidates are in Phase II stage, three drug candidates are in Phase I stage, eight drug candidates are in Pre-Clinical stage, three candidates are in discovery Phase. Herpes is an infection caused by a virus known as, herpes simplex virus. It is estimated that around 3.7 billion people under the age of 50 years are suffering with the herpes simplex virus infection, globally. The disease is categorized into two types: HSV1 and HSV2. HSV1, also known as oral herpes can lead to sores on the mouth and around the lips. HSV2 causes genital herpes, and is a sexually-transmitted virus which is a leading cause of recurrent genital herpes worldwide. Various new therapies and advanced technologies are driving the growth of Herpes simplex virus infections pipeline.

Explore Report Overview at: www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis

Insights on pipeline segments

As per the findings of the research, around 20.0% of drug candidates for the treatment of Herpes simplex virus infections Therapeutic pipeline are being developed to be administered by oral route,15.0% by intravenous route, 40.0% are not disclosed and 25.0% are to be administered by other routes which includes sublingual, intramuscular and Topical.

Explore Report Sample at: www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample

Major companies collaborate for the development of Herpes simplex virus infections Pipeline

The research also found that various companies have collaborated for the development of Herpes simplex virus infections pipeline. In July 2013, NanoBio Corporation entered into an agreement with the Division of Microbiology and Infectious Diseases (DMID), a division of National Institute of Health. Under the agreement, DMID agreed to fund certain activities and studies in support of developing intranasal and intramuscular nanoemulsion vaccines for HSV-2. In June 2014, - PaxVax Inc., entered into a research and development collaboration with the University of California to develop a combination vaccine to prevent genital herpes simplex virus infections.

Browse Other Related report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the key players developing drugs for the treatment ofHerpes virus simplex infections include Maruho Co., Ltd., NanoBio Corporation, Lumavita AG, Shulov Innovate for Science Ltd. 2012, Beech Tree Labs, Inc.,Sanofi Pasteur, PaxVax Inc.,Vical, Inc., Immune Design Corp., Profectus BioSciences, Inc., Editas Medicine, Inc., GenVec, Inc., ViRAZE, JN-International Medical Corporation and AiCuris Anti-infective Cures GmbH.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.